Length: 5 min read
Published: April 27th 2026
Medically Reviewed: By Dr Aqua Asif

At a Glance

Prostate cancer is not one disease – it is a group of subtypes that behave differently. The most common is acinar adenocarcinoma (about 95% of cases), which is often slow-growing and may be suitable for active surveillance or focal therapy. Ductal adenocarcinoma, small cell carcinoma, transitional cell carcinoma, squamous cell carcinoma, and prostate sarcomas are rarer and typically more aggressive – they often don’t elevate PSA and need urgent specialist input.

Key Takeaways

  • Acinar adenocarcinoma – most common (95%) – slow-growing, low-risk cases may be managed with active surveillance.
  • Ductal adenocarcinoma, less common but more aggressive, often presents with a normal PSA.
  • Small cell carcinomas: a neuroendocrine tumor typically treated with chemotherapy, not hormone therapy.
  • Transitional cell carcinoma behaves like bladder cancer and needs a different pathway.
  • Recurrent prostate cancer salvage focal therapy (NICE IPG 424/IPG 768) is emerging for selected radio recurrent local tumors.
  • Small cell carcinoma is a highly aggressive neuroendocrine tumour that is typically managed with chemotherapy rather than standard hormone therapy.

Main types of prostate cancer

There are many forms of the disease, but people often ask what are the 4 types of prostate cancer they should know about. The main types usually include acinar adenocarcinoma, ductal adenocarcinoma, transitional cell carcinoma, and small cell carcinoma. Each of these types behaves differently and may need a different treatment plan.

The most common types of prostate cancer are adenocarcinomas. These develop in the gland cells of the prostate and make up the majority of diagnosed cases. These subtypes differ in their typical growth speed, presentation, and responsiveness to various therapeutic approaches.

Acinar adenocarcinoma

Acinar adenocarcinoma is the most common form of prostate cancer. It begins in the glandular cells that produce the fluid component of semen. PSA testing, MRI scans, and biopsies often detect it at early stages.

Depending on the specific risk group and individual patient factors, doctors may recommend:

  • Active surveillance (for selected men with low-risk or favourable intermediate-risk disease)
  • Focal Therapy (for carefully selected patients with localised tumours)
  • Radical prostatectomy (to surgically remove the prostate gland)
  • External beam radiotherapy (often combined with hormone therapy, for localised or locally advanced stages)

Many acinar adenocarcinomas grow slowly, and some men may live for years with careful monitoring alone without needing invasive treatment.

Ductal adenocarcinoma

It tends to grow faster and behaves more aggressively than typical acinar adenocarcinoma. Importantly, men with this subtype may present with normal PSA levels, meaning it is often detected later when urinary symptoms develop.

Treatments may involve:

  • Surgery to remove the prostate
  • Radiotherapy
  • Combined therapies if the cancer is advanced

Because of its aggressive nature, ductal adenocarcinoma often requires a prompt, comprehensive plan.

Get Expert Advice & The Latest Research

Subscribe to our newsletter to receive the latest updates, expert insights, and breakthrough research on prostate cancer-delivered straight to your inbox.

    Rarer types of prostate cancer

    Rare types of prostate cancer differ significantly from standard adenocarcinomas. They often do not produce PSA, making early detection more challenging. These cases almost always necessitate care at specialist centres following an urgent urology referral.

    Transitional cell carcinoma

    Transitional cell carcinoma, also known as urothelial carcinoma, typically begins in the cellular lining of the bladder or urethra. It behaves biologically like high-grade bladder cancer rather than conventional prostate cancer.

    Treatments may include:

    • Radical surgery
    • Chemotherapy for advanced cases
    • Radiotherapy

    Here is a brief comparison between transitional cell carcinoma and acinar adenocarcinoma:

    Feature Transitional cell carcinoma Acinar adenocarcinoma
    Origin Urothelial lining of the urethra or bladder Prostate gland cells
    PSA Elevation Rare Common
    Aggressiveness Moderate to high Highly variable
    Main Treatment Surgery, chemotherapy, radiotherapy Active surveillance, surgery, radiotherapy, or focal therapy

    Squamous cell carcinoma

    Squamous cell carcinoma grows from the flat, scale-like cells inside the prostate. It is very rare and does not behave like typical prostate cancers. Because PSA levels typically remain normal, early detection is difficult, and diagnosis often occurs only after significant symptoms arise.

    Medical teams may suggest:

    • Surgery or radiotherapy
    • Systemic chemotherapy if the cancer has spread

    This subtype is generally entirely resistant to standard hormone therapy.

    Small cell carcinoma

    Small cell carcinoma is a type of neuroendocrine tumour. It grows fast and often spreads before being diagnosed. Because the cells do not produce PSA, standard blood tests are unreliable for detection or monitoring.

    Treatment usually relies on:

    • Chemotherapy as the primary intervention
    • Radiotherapy
    • Surgery in highly selected cases

    Hormone therapy is generally ineffective when this cancer occurs in isolation.

    Sarcomas

    Sarcomas are extremely rare in the prostate. They form in muscle, fat, or connective tissue rather than glandular cells. Unlike adenocarcinomas, they can affect younger patients. PSA levels are usually normal.

    Examples of prostate sarcomas include:

    • Leiomyosarcoma
    • Rhabdomyosarcoma

    Management typically involves an expert multidisciplinary team using a combination of aggressive surgery, tailored chemotherapy, and radiotherapy.

    Recurrent prostate cancer

    Prostate cancer can return following primary treatment. This recurrence may be localised to the prostate bed or present as distant metastases. A rising PSA is frequently the first clinical sign of recurrence. Published evidence suggests that biochemical recurrence occurs in around 20–50% of men within 10 years after radical local treatment.

    Exploring treatment options is a highly individualised process. Options may include:

    • Hormone therapy.
    • Salvage radiotherapy following primary surgery.
    • Salvage focal therapy.

    Emerging clinical data suggests that for carefully selected men with a radiorecurrent local tumour, salvage focal therapy may offer effective cancer control (85% within 5 years) while aiming to preserve urinary continence and minimise severe complications. It is important to prepare questions to ask your urologist to determine if you are a suitable candidate for these advanced interventions.

    FAQs

    Q: What is the most aggressive form of prostate cancer?
    A: Small cell carcinoma, a type of neuroendocrine tumour, is generally considered one of the most aggressive forms of prostate cancer. It grows rapidly and often spreads to other organs early in its course. Because it does not produce PSA, it is frequently diagnosed at an advanced stage and is typically managed with systemic chemotherapy.
    Q: What is the most treatable prostate cancer?
    A: Low-grade acinar adenocarcinoma is highly treatable when detected early. Many men with localised, low-risk disease are excellent candidates for active surveillance. For those requiring intervention, options such as surgery, radiotherapy, or focal therapy are associated with excellent long-term survival outcomes.
    Q: What prostate cancer doesn’t need treatment?
    A: Many low-risk acinar adenocarcinomas grow so slowly that they may never cause harm or require active treatment. These are often safely managed with active surveillance, a structured programme of regular PSA tests, MRI scans, and biopsies designed to carefully monitor the prostate and only trigger treatment if the disease shows signs of progression.

    References

    European Association of Urology. (2026). EAU Guidelines on Prostate Cancer. Available at: https://uroweb.org/guidelines/prostate-cancer

    Light, A., et al. (2026). Salvage Focal Therapy vs Radical Prostatectomy for Localized Radiorecurrent Prostate Cancer. JAMA Oncology.

    National Institute for Health and Care Excellence. (2021). Prostate cancer: diagnosis and management (NG131). Available at: https://www.nice.org.uk/guidance/ng131

    Prostate Cancer UK. (2022). Rare prostate cancer. Available at: https://prostatecanceruk.org/prostate-information-and-support/further-information/rare-prostate-cancer

    About UsBook Consultation